硼替佐米不同给药方案在VRd一线治疗多发性骨髓瘤中的结局
该回顾性研究分析了555例新诊断多发性骨髓瘤患者接受VRd方案时硼替佐米的三种给药方案。结果显示每周两次给药周围感觉神经病变更常见但起效更快,每周一次每21天方案VGPR及以上率更高,但各组无进展生存期和总生存期无差异。
要点
- 不同给药方案间PFS和OS无显著差异。
核心结论
- 硼替佐米不同给药方案在VRd一线治疗NDMM中虽响应率有微小差异,但对PFS或OS无显著影响。
主要发现
- 硼替佐米给药方案:43%每周两次每21天,41%每周一次每21天,16%每周一次每28天。
- 中位随访37个月(IQR 22-56),各组PFS和OS无差异。
临床怎么用
- 结果支持当前每周一次给予硼替佐米的实践,因缺乏大型比较试验。
局限性
- 回顾性研究设计,缺乏大型随机试验比较硼替佐米给药方案修改。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Induction therapy for multiple myeloma with bortezomib (Velcade), lenalidomide (Revlimid), and dexamethasone (d) (VRd) was traditionally administered as bortezomib given twice weekly on a 3 week cycle. A modified schedule of weekly bortezomib has been adopted over time to decrease treatment burden for patients and reduce treatment-emergent neuropathy. This study evaluates the response rates and outcomes with different schedules of bortezomib in VRd administered for first-line treatment for patients with newly diagnosed MM (NDMM). We retrospectively analyzed patients treated with upfront VRd from June 30th 2008 to December 31st 2018, for variations of bortezomib administration. Five hundred and fifty-five (555) NDMM patients met inclusion criteria; median age 63 years and 61% men. Bortezomib was administered twice weekly every 21 days in 43%, once weekly every 21 days in 41% and once weekly every 28 days in 16%. Though peripheral sensory neuropathy was more frequent with twice weekly dosing (P = .002), this group achieved shorter time to best response (P = .01). Weekly every 21-day treatment saw higher VGPR or better rates (P = .02). However, with median follow up time of 37 months (IQR 22-56), we found no difference in PFS or OS among the groups. While small differences in response rates were found among the varying administration schedules of bortezomib administration, there was no significant effect on PFS or OS. Given that VRd remains a first line standard of care option for newly diagnosed MM, in the absence of a large trial comparing bortezomib dosing schedule modifications, these results are helpful in supporting current practices of once weekly administration.
引用
- Cook J, Johnson I, Higgins A, et al. Outcomes with different administration schedules of bortezomib in bortezomib, lenalidomide and dexamethasone (VRd) as first-line therapy in multiple myeloma. Am J Hematol. 2021. PMID: 33326116. doi:10.1002/ajh.26074
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。